FDA to review market authorisation application for atogepant for the preventive treatment of migraine

US regulatory review of this oral calcitonin gene-related peptide (CGRP) receptor antagonist for the preventive treatment of episodic migraine in adults is expected to conclude towards the end of the year. Application is supported by data from the phase III ADVANCE study.

Biospace Inc.